DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2227-2236

  Biroccio, Annamaria ^a   Porru, Manuela ^a   Rizzo, Angela ^a   Salvati, Erica ^a   D'Angelo, Carmen ^a   Orlandi, Augusto ^b   Passeri, Daniela ^b   Franceschin, Marco ^c   Stevens, Malcolm F G ^f   Gilson, Eric ^g   Beretta, Giovanni ^d   Zupi, Gabriella ^a   Pisano, Claudio ^e   Zunino, Franco ^d   Leonetti, Carlo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Sigma Tau SpA   (Italy)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,11 DIFLUORO 6,8,13 TRIMETHYL 8H QUINO[4,3,2 KL]ACRIDINIUM METHOSULFATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CORON; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GIMATECAN; HISTONE H2AX; IDN 5174; IND 5174; NAMITECAN; PIP PIPER; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CANCER INHIBITION; CELL STRAIN HT29; CHROMATIN IMMUNOPRECIPITATION; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TELOMERE; TUMOR REGRESSION;

ACRIDINES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; COLONIC NEOPLASMS; DNA DAMAGE; DRUG SYNERGISM; G-QUADRUPLEXES; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; MICE; MICE, NUDE; TELOMERE; TOPOISOMERASE I INHIBITORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954568864     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3033     Document Type: Article

References (42)

1. Gellert M, Lipsett MN, Davies DR. Helix formation by guanylic acid. Proc Natl Acad Sci U S A 1962;48:2013-8.
2. Drygin D, Siddiqui-Jain A, O'Brien S, Schwaebe M, Lin A, Bliesath J, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res 2009;69:7653-61.
3. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009;86:151-64.
4. Gilson E, Géli V. How telomeres are replicated. Nat Rev Mol Cell Biol 2007;8:825-38. (Pubitemid 47462137)
5. Giraud-Panis MJ, Pisano S, Poulet A, Le Du MH, Gilson E. Structural identity of telomeric complexes. FEBS Lett 2010;584:3785-99.
6. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 2007;318:798-801. (Pubitemid 351411771)
7. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503-14. (Pubitemid 29231173)
8. Oganesian L, Bryan TM. Physiological relevance of telomeric Gquadruplex formation: a potential drug target. Bioessays 2007;29:155-65. (Pubitemid 46340250)
9. Han H, Hurley LH. G-quadruplex DNA: a potential target for anticancer drug design. Trends Pharmacol Sci 2000;21:136-42. (Pubitemid 30190138)
10. Blackburn EH. The end of the (DNA) line. Nat Struct Biol 2000;7:847-50.
11. Brower V. Telomerase-based therapies emerging slowly. J Natl Cancer Inst 2010;102:520-1.
12. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 2002;30:839-65. (Pubitemid 34679653)
13. Biroccio A, Leonetti C. Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocr Relat Cancer 2004;11:407-21. (Pubitemid 39331274)
14. Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ, Double JA, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 2005;65:1489-96. (Pubitemid 40270178)
15. Tauchi T, Shin-Ya K, Sashida G, Sumi M, Nakajima A, Shimamoto T, et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 2003;22:5338-47. (Pubitemid 37056096)
16. Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R, et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest 2007;117:3236-47. (Pubitemid 350096981)
17. Tauchi T, Shin-ya K, Sashida G, Sumi M, Okabe S, Ohyashiki JH, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 2006;25:5719-25. (Pubitemid 44435249)
18. Phatak P, Cookson JC, Dai F, Smith V, Gartenhaus RB, Stevens MF, et al. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 2007;96:1223-33. (Pubitemid 46625068)
19. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 2002;61:1154-62. (Pubitemid 34441781)
20. Leonetti C, Scarsella M, Riggio G, Rizzo A, Salvati E, D'Incalci M, et al. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res 2008;14:7284-91.
21. Gunaratnam M, Green C, Moreira JB, Moorhouse AD, Kelland LR, Moses JE, et al. G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo. Biochem Pharmacol 2009;8:5-122.
22. Rizzo A, Salvati E, Porru M, D'Angelo C, Stevens MF, D'Incalci M, et al. Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Res 2009;37:5353-64.
23. Heald RA, Modi C, Cookson JC, Hutchinson I, Laughton CA, Gowan SM, et al. Antitumor polycyclic acridines 8 synthesis and telomeraseinhibitory activity of methylated pentacyclic acridinium salts. J Med Chem 2002;45:590-97. (Pubitemid 34145706)
24. Ye J, Lenain C, Bauwens S, Rizzo A, Saint-Léger A, Poulet A, et al. TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell 2010;142:230-42.
25. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75:1262-71. (Pubitemid 351305209)
26. Beretta GL, Petrangolini G, De Cesare M, Pratesi G, Perego P, Tinelli S, et al. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. Cancer Res 2006;66:10976-82. (Pubitemid 44876997)
27. Pisano C, De Cesare M, Beretta GL, Zuco V, Pratesi G, Penco S, et al. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol Cancer Ther 2008;7:2051-9.
28. De Cesare M, Pratesi G, Veneroni S, Bergottini R, Zunino F. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clin Cancer Res 2004;10:7357-64. (Pubitemid 39487725)
29. Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, et al. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol 2010;21:759-65.
30. Dallavalle S, Ferrari A, Biasotti B, Merlini L, Penco S, Gallo G, et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 2001;20:3264-74. (Pubitemid 32917106)
31. Dallavalle S, Delsoldato T, Ferrari A, Merlini L, Penco S, Carenini N, et al. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem 2000;43:3963-69.
32. Casagrande V, Alvino A, Bianco A, Ortaggi G, Franceschin M. Study of binding affinity and selectivity of perylene and coronene derivatives towards duplex and quadruplex DNA by ESI-MS. J Mass Spectrom 2009;44:530-40.
33. Brunori M, Mathieu N, Ricoul M, Bauwens S, Koering CE, Roborel de Climens A, et al. TRF2 inhibition promotes anchorage independent growth of telomerase-positive human fibroblasts. Oncogene 2006;25:990-7. (Pubitemid 43277007)
34. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996;88:419-29. (Pubitemid 26097058)
35. Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate 2007;67:1475-85. (Pubitemid 47435794)
36. Petrangolini G, Tortoreto M, Perego P, Carenini N, De Cesare M, Balsari A, et al. Combination of metronomic gimatecan and CpG oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther 2008;7:596-601. (Pubitemid 351847037)
37. Geran RI, Greenberg NH, Macdonald MM, Shumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 1972;3(Pt 3):1-88.
38. Neidle S. Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer. FEBS J 2010;277:1118-25.
39. Arimondo PB, Riou JF, Mergny JL, Tazi J, Sun JS, Garestier T, et al. Interaction of human DNA topoisomerase I with G-quartet structures. Nucleic Acids Res 2000;28:4832-8. (Pubitemid 32014252)
40. Laine JP, Opresko PL, Indig FE, Harrigan JA, von Kobbe C, Bohr VA. Werner protein stimulates topoisomerase I DNA relaxation activity. Cancer Res 2003;63:7136-46. (Pubitemid 37413451)
41. Mohaghegh P, Karow JK, Brosh RM. Jr., Bohr VA, Hickson ID. The Bloom0s and Werner's syndrome proteins are DNA structure-specific helicases. Nucleic Acids Res 2001;29:2843-9. (Pubitemid 32685049)
42. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802. (Pubitemid 44450467)